Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Etoposide in Pediatric Refractory Solid Tumors
NCT01294670Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2011
- Primary completion
- Dec 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in solid tumor and sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Dose Limiting Toxicity at 3 weeks, Maximum Tolerated Dose at 1 year and 1 more. Started Feb 2011; status: completed.
02
Drugs
vorinostat
03
Conditions
solid tumorsarcoma
Beyond the preview
Go deeper on NCT01294670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294670.